Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.61 |
| ▸ | NQO1 | P15559 | 3/20 | 0.60 |
| ▸ | VKORC1 | Q9BQB6 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106117 | 0.93 | ADORA3 (0.70) | ADORA3CYP2C9NQO1VKORC1KDM4E | |
| SCHEMBL5107024 | 0.89 | ADORA3 (0.86) | ADORA3CYP2C9NQO1VKORC1KDM4E | |
| SCHEMBL5103750 | 0.86 | CYP2C9 (0.66) | ADORA3CYP2C9NQO1VKORC1KDM4E | |
| SCHEMBL5103329 | 0.84 | ADORA3 (0.60) | ADORA3CYP2C9NQO1VKORC1KDM4E | |
| SCHEMBL5103288 | 0.83 | NQO1 (0.85) | ADORA3CYP2C9NQO1VKORC1KDM4E | |
| SCHEMBL5103335 | 0.81 | NQO1 (0.65) | ADORA3CYP2C9NQO1VKORC1KDM4E | |
| Ethyl Biscoumacetate SCHEMBL29359768 | 0.81 | ADORA3 (1.00) | ADORA3CYP2C9NQO1VKORC1KDM4E | |
| Ethyl Biscoumacetate SCHEMBL42830 | 0.81 | ADORA3 (1.00) | ADORA3CYP2C9NQO1VKORC1KDM4E | |
| SCHEMBL6822511 | 0.81 | ADORA3 (0.51) | ADORA3CYP2C9NQO1VKORC1KDM4E | |
| SCHEMBL7350670 | 0.80 | CYP2C9 (0.76) | CYP2C9NQO1VKORC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | claimed |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | disclosed |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | ARYX THERAPEUTICS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-7145020-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2006-12-05 | — | — | US | disclosed |
| US-6864279-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040220258-A1 | Materials and methods for treating coagulation disorders | ESPERO BIOPHARMA, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS, INC. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885CYP2C9 24/4885NQO1 249/4885 |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885CYP2C9 24/4885NQO1 249/4885 |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885CYP2C9 24/4885NQO1 249/4885 |
| US-20040220258-A1 | Materials and methods for treating coagulation disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885CYP2C9 24/4885NQO1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.